The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania
NCT ID: NCT03851419
Last Updated: 2023-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2584 participants
OBSERVATIONAL
2018-04-01
2021-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Furthermore, the immune system response in HIV patients with Taenia solium neurocysticercosis will be assessed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
People living with HIV
People living with HIV (ART naive or on ART)
Diagnosis of (Neuro)cysticercosis
* Serological tests for cysticercosis
* Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis
* Stool testing for T. solium
People not infected with HIV
HIV-negative people. Each participant is matched for age, sex and location to a study participant living with HIV
Diagnosis of (Neuro)cysticercosis
* Serological tests for cysticercosis
* Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis
* Stool testing for T. solium
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diagnosis of (Neuro)cysticercosis
* Serological tests for cysticercosis
* Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis
* Stool testing for T. solium
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients of age 14 years and above
* Patient living inside the study catchment area
* HIV-positive patients
* Patient suspected of taeniasis or cysticercosis/neurocysticercosis
Exclusion Criteria
* Study participants taking anthelminthic drugs PZQ and ALB or have received them within the previous 12 months.
* Pregnant women
* Patients that are seriously ill.
* Patients with epilepsy and other mental disorders that impair thoughts and emotions such as psychosis.
14 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute for Medical Research, Tanzania
OTHER_GOV
Kilimanjaro Clinical Research Institute
OTHER
Muhimbili University of Health and Allied Sciences
OTHER
Technical University of Munich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bernard J Ngowi, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
National Institute for Medical Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute of Medical Research
Dar es Salaam, , Tanzania
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CYSTINET-Africa Tz II
Identifier Type: -
Identifier Source: org_study_id